Skip to main content

Articles

Original Research
Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis
Avery A. Rizio, PhD; Michelle K. White, PhD; Kristen L. McCausland, MPH, PhD; Tiffany P. Quock, MS, PhD; Spencer D. Guthrie, MS, MBA, MPH; Miyo Yokota, PhD; Martha S. Bayliss, MS, MSc
Read More
Perspectives
Unscaling Population Health
David B. Nash, MD, MBA
Read More
Original Research, Practice Management
Healthcare Costs and Absenteeism Among Caregivers of Adults with Partial-Onset Seizures: Analysis of Claims from an Employer Database
Richard A. Brook, MS, MBA; Krithika Rajagopalan, PhD; James E. Smeeding, RPh, MBA
Stakeholder Perspective
The Importance of Clinical and Economic Support Systems for Caregivers
Michael Kleinrock
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Ibrutinib 7-Year Follow-Up Data in First-Line and Relapsed/Refractory Patients with CLL/SLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk CLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression-Free Survival Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Results from the Phase 3 iLLUMINATE Study: Ibrutinib + Obinutuzumab as First-Line Treatment in Patients with CLL/SLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed/Refractory CLL
Read More
Page 63 of 244
Results 621 - 630 of 2434